Blood, 1 November 2004, Vol. 104, No. 9, pp. 2675-2681.
Prepublished online as a Blood First Edition Paper on July 1, 2004; DOI 10.1182/blood-2004-02-0567.
 Previous Article | Table of Contents | Next Article 
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation
Pierre Feugier,
Eric Labouyrie,
Malika Djeridane,
Arash Jenabian,
Viviane Dubruille,
Christian Berthou,
Christiane Ghandour,
Bernard Desablens,
Yasmine Chaït,
Philippe Casassus,
Vincent Delwail,
Norbert Ifrah,
Annick Le Mevel,
Thierry Lamy,
Josette Brière,
Pierre Colonna, and
Jean-Marie Andrieu
From Hématologie, Hôpitaux de Brabois, Nancy, France; Cancérologie médicale, Hôpital Européen Georges Pompidou, Paris, France; Hématologie, Hôtel-Dieu, Nantes, France; Hématologie, Hôpital Morvan, Brest, France; Cabinet de Médecine Interne-Hématologie, Rennes, France; Hématologie, Hôpital Sud, Amiens, France; Hématologie, Hôpital Beaujon, Paris, France; Hématologie, Hôpital Avicenne, Bobigny, France; Oncologie hématologique et Thérapie cellulaire, Hôpital La Milétrie, Poitiers, France; Hématologie, Centre Hospitalier et Universitaire, Angers, France; Centre René Gauducheau, Nantes, France; Hématologie, Centre Hospitalier et Universitaire, Rennes, France; and Anatomie Pathologique, Hôpital Saint-Louis, Paris, France.
Lymphocyte-predominant Hodgkin lymphoma (LPHL), according to the Revised European-American Lymphoma classification, was considered on a retrospective basis as a specific clinical entity with a large majority of patients at clinical stage (CS) IA or IIA. Of the 500 patients with CS IA/IIA Hodgkin lymphoma (HL) prospectively treated between 1981 and 1996 by one or 3 courses of anthracycline-based chemotherapies combined with high-dose extended irradiation, disease in 42 patients was reclassified as LPHL. These 42 patients, none of whom had mediastinal involvement (MI), were compared with the 458 patients with classical HL (cHL), 144 without MI and 314 with MI. Surprisingly, the male-female ratio, age, first site involved, hemoglobin level, lymphocyte count, and sedimentation rate of patients with LPHL and cHL without MI were identical and significantly different from those of patients with cHL with MI. Moreover, 15-year HL mortality rates were similarly low in patients with LPHL (2.4%) and cHL without MI (0.7%). Overall survival rates were also similar (86% and 82%) and as high as 100% and 95% in patients treated before the age of 40 years. This study demonstrated that LPHL and cHL without MI shared the same presenting characteristics and the same excellent long-term prognosis after a brief anthracycline-based chemotherapy plus high-dose extended irradiation. (Blood. 2004;104:2675-2681)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. S. Abramson
T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management.
Oncologist,
April 1, 2006;
11(4):
384 - 392.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Nogova, T. Rudiger, and A. Engert
Biology, Clinical Course and Management of Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Hematology,
January 1, 2006;
2006(1):
266 - 272.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. P. Canellos
Chemotherapy Alone for Early Hodgkin's Lymphoma: An Emerging Option
J. Clin. Oncol.,
July 20, 2005;
23(21):
4574 - 4576.
[Full Text]
[PDF]
|
|
|
|
|
